Related references
Note: Only part of the references are listed.Multi-spectroscopic and molecular modeling approaches to elucidate the binding interaction between bovine serum albumin and darunavir, a HIV protease inhibitor
Jie-Hua Shi et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2018)
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor
Yuxian He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir
Fengling Liu et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Selection of T1249-resistant human immunodeficiency virus type 1 variants
Dirk Eggink et al.
JOURNAL OF VIROLOGY (2008)
The contents of the syringe
Steven Salzberg
NATURE (2008)
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants
Patrick J. Collins et al.
NATURE (2008)
Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency
John J. Dwyer et al.
PROTEIN SCIENCE (2008)
Perspective - HIV vaccine research: The way forward
Anthony S. Fauci et al.
SCIENCE (2008)
The global circulation of seasonal influenza A (H3N2) viruses
Colin A. Russell et al.
SCIENCE (2008)
Design of HIV protease inhibitors targeting protein backbone: An effective strategy for combating drug resistance
Arun K. Ghosh et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Molecular analysis of the HIV-1 resistance development:: Enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants
Milan Kozisek et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Respiratory syncytial virus infection in 406 hospitalized premature infants:: results from a prospective German multicentre database
Arne Simon et al.
EUROPEAN JOURNAL OF PEDIATRICS (2007)
The design of drugs for HIV and HCV
Erik De Clercq
NATURE REVIEWS DRUG DISCOVERY (2007)
Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249
T. Melby et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
Potent D-peptide inhibitors of HIV-1 entry
Brett D. Welch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Structural basis of viral invasion: lessons from paramyxovirus F
Robert A. Lamb et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2007)
Conformational flexibility in the flap domains of ligand-free HIV protease
Holly Heaslet et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2007)
Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease
Sripriya Chellappan et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2007)
Structure of a high-affinity Mimotope peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies
Erica Ollmann Saphire et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue
Raghavan Chinnadurai et al.
JOURNAL OF VIROLOGY (2007)
GS-8374, a novel phosphonate HIV protease inhibitor with potent in vitro antiretroviral activity, low metabolic toxicity, and favorable resistance profile
Christian Callebaut et al.
ANTIVIRAL RESEARCH (2007)
Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations
S. Muzammil et al.
JOURNAL OF VIROLOGY (2007)
Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors
Shuji Hatakeyama et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
HIV gp41 C-terminal heptad repeat contains multifunctional domains - Relation to mechanisms of action of anti-HIV peptides
Shuwen Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10
Rosa M. F. Cardoso et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
Robert W. Shafer et al.
AIDS (2007)
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism
Monique Nijhuis et al.
PLOS MEDICINE (2007)
Vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants
Xiaodong Zhao et al.
JOURNAL OF VIROLOGY (2006)
Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring
Tomas Cihlar et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
Rupert J. Russell et al.
NATURE (2006)
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis
Jing Lu et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Kinetic dependence to HIV-1 entry inhibition
H. Kirby Steger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients
Beatrice Labrosse et al.
JOURNAL OF VIROLOGY (2006)
Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody
Micah A. Luftig et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Computational simulations of HIV-1 proteases-multi-drug resistance due to nonactive site mutation L90M
Hirotaka Ode et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385
JF Miller et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385
PJ Yates et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States
RA Bright et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation
HS Yin et al.
NATURE (2006)
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern
RA Bright et al.
LANCET (2005)
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro
M Mink et al.
JOURNAL OF VIROLOGY (2005)
Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir
L Doyon et al.
ANTIVIRAL RESEARCH (2005)
Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein
HS Yin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
S De Meyer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vivo selection of respiratory syncytial viruses resistant to palivizumab
XD Zhao et al.
JOURNAL OF VIROLOGY (2005)
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor
DLNG Surleraux et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41
RMF Cardoso et al.
IMMUNITY (2005)
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV
JJ Eron et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5
MB Zwick et al.
JOURNAL OF VIROLOGY (2004)
Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III
MC Lawrence et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Resistant influenza A viruses in children treated with oseltarnivir: descriptive study
M Kiso et al.
LANCET (2004)
Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants
XD Zhao et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
JA Binley et al.
JOURNAL OF VIROLOGY (2004)
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor
NM King et al.
JOURNAL OF VIROLOGY (2004)
Influenza viruses resistant to the antiviral drug oseltamivir: Transmission studies in ferrets
ML Herlocher et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope
G Ofek et al.
JOURNAL OF VIROLOGY (2004)
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition
DA Calarese et al.
SCIENCE (2003)
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: Structural insights for better antiviral therapy
M Prabu-Jeyabalan et al.
JOURNAL OF VIROLOGY (2003)
Specificity and promiscuity in protein-ligand and protein-protein interactions
PM Colman et al.
AUSTRALIAN JOURNAL OF CHEMISTRY (2003)
Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations
S Piana et al.
PROTEIN SCIENCE (2002)
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to 150V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro
MF Maguire et al.
JOURNAL OF VIROLOGY (2002)
Modelling the structure of the fusion protein from human respiratory syncytial virus
BJ Smith et al.
PROTEIN ENGINEERING (2002)
Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes
M Prabu-Jeyabalan et al.
STRUCTURE (2002)
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
LV Gubareva et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design
EO Saphire et al.
SCIENCE (2001)
The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion
L Chen et al.
STRUCTURE (2001)
Protein design of an HIV-1 entry inhibitor
MJ Root et al.
SCIENCE (2001)
Management of influenza - Use of new antivirals and resistance in perspective
HC Jackson et al.
CLINICAL DRUG INVESTIGATION (2000)
Resistance of influenza viruses to neuraminidase inhibitors - a review
JL McKimm-Breschkin
ANTIVIRAL RESEARCH (2000)
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies
JM Barnett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease
M Prabu-Jeyabalan et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Share Paper
